Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

3.060 -0.070 (-2.24%)
Streaming Delayed Price Updated: 9:30 AM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 494
Open 3.060
Bid (Size) 3.060 (6)
Ask (Size) 3.270 (3)
Prev. Close 3.130
Today's Range 3.060 - 3.060
52wk Range 2.839 - 9.614
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire

Performance

YTD
-53.64%
-53.64%
1 Month
-1.61%
-1.61%
3 Month
-34.05%
-34.05%
6 Month
-52.63%
-52.63%
1 Year
-56.53%
-56.53%

More News

Read More
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Where Mainz Biomed Stands With Analysts
Via Benzinga
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
Via Benzinga
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
From Mainz BioMed NV
Via GlobeNewswire
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
Via News Direct
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Via Benzinga
Exposures COVID-19
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
Via Benzinga
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
From Mainz BioMed NV
Via GlobeNewswire
Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible
Via News Direct
Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech
Via Benzinga
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Secures up to $50M in New Funding
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
From Mainz BioMed NV
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.